Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Editor in Chief at Blood Cancer Journal, shared on X:
“Forgotten myeloma history series.
I see PANGEA and other models to predict risk of progression in smoldering myeloma based on evolving changes in M protein and hemoglobin during follow up. But sometimes history is forgotten.
We showed this 10 years ago almost to the date. Our model is the simplest and doesn’t need calculators: 0.5 gm/dL increase in M protein occurring concurrently with 0.5 gm/dL drop in hemoglobin qualifies as high risk SMM with >80% risk of progression in 2 years. If the marrow is 20% or more, the risk is >90% in 2 years.”
Title: Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
Authors: P. Ravi, S. Kumar, J. T. Larsen, W. Gonsalves, F. Buadi, M. Q. Lacy, R. Go, A. Dispenzieri, P. Kapoor, J. A. Lust, D. Dingli, Y. Lin, S. J. Russell, N. Leung, M. A. Gertz, R. A. Kyle, P. L. Bergsagel, S. V. Rajkumar.
You can also read: ‘ENDURANCE Trial: 2 Years of Lenalidomide Maintenance Matches Continuous Therapy in Standard-Risk Multiple Myeloma‘
